WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 10-December-2019 (data as of 10-December-2019)
Next overall update June 2020
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 40'8501 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 40'7861 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 8'382  8'244  8'109  7'978  7'854  5'946  4'448  3'701 
Births 170  170  169  168  167  126  99  92 
Surviving infants 170  169  169  168  166  125  98  91 
Pop. less than 5 years 846  843  835  822  808  607  477  453 
Pop. less than 15 years 2'341  2'304  2'265  2'223  2'181  1'670  1'390  1'222 
Female 15-49 years 3'916  3'858  3'802  3'751  3'701  2'963  2'186  1'729 

Number of reported cases

(Click for retrospective incidence data for Israel)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  3'177  42  80  36  230  215 
Mumps
ChartChart
  239  353  51  47  140  48 
Pertussis
ChartChart
  706  467  1'143  5'338  1'509  452  155  19 
Polio*
ChartChart
  11 
Rubella
ChartChart
  54 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Israel)
Vaccine year result method % card seen                                                
BCG          75 
DTP1          99  99  94  95  95  96  97  94 
DTP3          98  98  94  95  95  96  93  84 
IPV1          99  99 
HepB_BD          95  96  97  99* 
HepB3          96  97  95  96  97  97 
Hib3          98  98  94  95  95  94 
JapEnc         
MCV1          98  98  97  98  97  97  91  81 
MCV2          96  96  97  97  96 
MenA         
PCV1          98  99 
PCV2          97  97 
PCV3          95  94  93  94  94 
Pol3          98  98  94  95  95  92  93  85 
Rota1          92  93 
RotaC          81  81  81  80  81 
RCV1          98  98  97  98  97 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Israel)
BCG
  75 
DTP1
ChartChart
  99  99  94  95  95  95  97  94 
DTP3
ChartChart
  98  98  94  95  95  93  93  84 
HepB3
ChartChart
  97  97  95  96  97  98 
HepB_BD
ChartChart
  95  95  95  96  97  96 
Hib3
ChartChart
  98  98  94  95  95  93 
IPV1
  99  99  94  95 
MCV1
ChartChart
  98  98  97  98  97  95  91  81 
MCV2
ChartChart
  96  96  97  97  96 
PCV3
ChartChart
  94  94  93  94  94 
Pol3
ChartChart
  98  98  94  95  95  93  93  85 
RCV1
ChartChart
  98  98  97  98  97  95 
RotaC
ChartChart
  81  81  81  80  81 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 15  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes risk groups
DT 2, 4, 6, 12 months; Yes if Pertussis contraindicated
DTaPHibIPV 2, 4, 6, 12 months; Yes
HepA_Adult Yes risk groups and travellers
HepA_Pediatric 18, 24 months; Yes
HepB_Adult Yes risk groups and travellers
HepB_Pediatric birth; 1, 6 months; Yes and risk groups
HPV 13 years; +6 months; Yes females and males
Influenza_Adult >18 years; Yes and adults with chronic conditions, pregnant women, healthcare workers, residents living in long-term care facilities, Hajj and other travellers, other risk groups
Influenza_Pediatric 6 months-18 years; Yes and children with chronic conditions
IPV Yes risk groups, catch-up
JE_Inactd Yes travellers
MenACWY-135 conj Yes risk groups
MenB Yes risk groups
MMRV 12 months; 6 years; Yes
OPV 6, 18 months; Yes
Pneumo_conj 2, 4, 12 months; Yes and at 6 months for risk groups
Pneumo_ps >=65 years; Yes and risk groups
Rotavirus 2, 4, 6 months; Yes
TBE Yes travellers (paediatric and adult)
Td Yes every ten years to adult population and for tetanus prophilaxis in wound management
Tdap 13 years; Yes and adults in risk group and pregnant women
TdaPIPV 7 years; Yes and at-risk adults
TT Yes tetanus prophilaxis in wound management
Typhoid_conj Yes travellers
TyphoidHepA Yes travellers
Typhoid_ps Yes travellers
Varicella Yes catch-up and risk groups
YF Yes travellers
Zoster >=60 years; Yes

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2019-2029  2018-2028       
Nº of districts with microplans that include activities to raise immunization coverage number 15  15  15  15  15  15  15 

System performance

Total Nº districts in country number 15  15  15      15  15 
Nº districts with DTP3 coverage >=80% number 15  15  15  15  15  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100      100  100 
Nº districts with measles (MCV1) coverage >=95% number 15  15  15  15  12  15  15 
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100      100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.